Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Anna WexlerDepartment of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-6723-9038
David W OslinDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Bruno MilletDepartment of Psychiatry, Paris Brain Institute, Pitie-Salpetrière Hospital, Sorbonne University, Paris, France.
Katherine W ScangosDepartment of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-7983-7767
Bijan PesaranDepartment of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
A Eden EvinsCenter for Addiction Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Anna Rose ChildressDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Casey H HalpernDepartment of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. casey.halpern@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0003-3907-216X
Funding
Clinical Translation of Ultrasonic Ketamine Uncaging for Non-Opioid Therapy of Chronic PainUG3NS115637 · NINDS · STANFORD UNIVERSITY · PI Raag D Airan, Boris Dov Heifets · 2019 to 2026
$8.0M
Efficacy of biomarker-guided rTMS for treatment resistant depressionR01MH118388 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI BHATI, MAHENDRA T, GUNNING, FAITH M · 2019 to 2025
$6.2M
Responsive Neurostimulation for Loss of Control EatingUH3NS103446 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI GOLD, JOSHUA I, HALPERN, CASEY HARRISON · 2019 to 2025
$4.8M
A translational approach for novel mechanisms of epigenetic regulation in treatment responses: toward a precision medicine modelR01MH128311 · NIMH · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Carla Nasca · 2022 to 2026
$3.6M
Remapping neurology through translation and innovationT32NS091008 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI AGUIRRE, GEOFFREY KARL, JENSEN, FRANCES E · 2015 to 2024
$3.0M
Utilizing changes in human brain connectivity to establish a dose-response relationship involved in the therapeutic actions of prefrontal brain stimulation on depression symptomsR01MH122754 · NIMH · STANFORD UNIVERSITY · PI WILLIAMS, NOLAN R. · 2020 to 2024
$2.7M
Tuning the brain from the outside in: a new way forward for treating mental health disorders and beyondDP1OD040905 · OD · UNIVERSITY OF PENNSYLVANIA · PI Casey Harrison Halpern · 2025 to 2026
$2.3M
Investigating the role of nucleus accumbens delta signaling in loss of controlR01MH124760 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI Casey Harrison Halpern · 2022 to 2026
$2.0M
Educating Physician Scientists in Psychiatry (EPSP): Firing up the next generation of translational and clinical neuroscientistsR25MH119043 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI Mariella De Biasi, MATTHEW S KAYSER · 2019 to 2026
Opioid use disorder (OUD) is a significant public health concern, with over 30% of the affected population not responding to available treatments. Severe OUD is characterized by drug-cue reactivity that has been reported to predict treatment failure. We leveraged this pathophysiological feature to optimize deep brain stimulation (DBS) of the nucleus accumbens region (NAc) in a male patient with OUD. A personalized drug-cue-reactivity task was administered while recording NAc electrophysiology from a lead externalized for clinical purposes. We identified a drug-cue-evoked electrophysiological signal in the ventral NAc that was associated with an elevated craving state and attenuated with stimulation delivered to the same area. This electrophysiological biomarker, along with behavioral assessments, informed the re-programming of DBS to a more focal and effective stimulation site. This resulted in sustained suppression of drug-related cravings. This study represents a proof-of-principle for a personalized, biomarker-informed neuromodulation strategy in OUD.
Indexed as
Deep Brain StimulationNucleus AccumbensOpioid-Related DisordersCravingCuesHumansMale
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Electrographic cue-reactivity co-localizes with accumbens deep brain stimulation in a case of opioid use disorder. · full record | Socratic